Centauri Therapeutics Limited, a London-based immunotherapy startup, has been awarded a £1 million grant from the PACE (Pathways to Antimicrobial Clinical Efficacy) programme. This funding will support the development of Centauri’s Alphamer™ technology, which targets Gram-negative bacteria, including Multi-Drug-Resistant (MDR) strains. The Alphamer™ platform harnesses the body’s natural immune response to fight life-threatening infections, offering a novel approach to treating infectious diseases.
The grant will also enable Centauri to expand its research across multiple therapeutic indications, including oncology. This investment highlights the potential of Centauri’s innovative technology to address the urgent need for effective anti-infectives and advance the field of immunotherapy.
#ImmuneTherapy #AntiInfectives #CentauriTherapeutics #PACEProgramme #Innovation #HealthTech #Biotech #SustainableHealthcare | Jennifer Schneider | Kara Carter | David Roblin
